Common Contracts
2 similar Agency Agreement contracts by Immunicon Corp, Stereotaxis, Inc.
2,389,877 Shares Series A Warrants to Purchase up to 1,792,408 Shares Series B Warrants to Purchase up to 2,148,739 Shares Series C Warrants to Purchase up to 341,412 Shares Series D Warrants to Purchase up to 341,412 Shares Stereotaxis, Inc. Common...Agency Agreement • December 29th, 2008 • Stereotaxis, Inc. • Electromedical & electrotherapeutic apparatus
Stereotaxis, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated in this Placement Agency Agreement (this “Agreement”) and the Subscription Agreements in the form of Exhibit A attached hereto (the “Subscription Agreements”) entered into with the investors identified therein (each, an “Investor” and collectively, the “Investors”), to issue and sell up to an aggregate of (i) 2,389,877 shares (the “Shares”) of the Company’s common stock, $0.001 par value per share (the “Common Stock”), (ii) Series A Warrants to purchase up to 1,792,408 shares of Common Stock (the “Series A Warrants”) in the form attached hereto as Exhibit B-1, (iii) Series B Warrants to purchase up to 2,148,739 shares of Common Stock (the “Series B Warrants”) in the form attached hereto as Exhibit B-2, (iv) Series C Warrants to purchase up to 341,412 shares of Common Stock (the “Series C Warrants”) in the form attached hereto as Exhibit B-3 and (v) Series D Warrants to purcha
30,000,000 Subordinated Convertible Notes Warrants to Purchase 1,466,994 Shares of Common Stock Immunicon Corporation PLACEMENT AGENCY AGREEMENTAgency Agreement • December 5th, 2006 • Immunicon Corp • Laboratory analytical instruments • New York
Immunicon Corporation, a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell (i) up to $30,000,000 in aggregate principal amount of unsecured subordinated convertible promissory notes (the “Notes”) and (ii) Warrants (the “Warrants”) to purchase up to an aggregate of 1,466,994 shares of the Company’s common stock, $0.001 par value per share (the “Common Stock”), to certain investors (each an “Investor” and, collectively, the “Investors”). The Notes and the Warrants are referred to herein collectively as the “Securities.” The Company desires to engage Deutsche Bank Securities Inc. (the “Placement Agent”) as its exclusive placement agent subject to the terms and conditions set forth in this Placement Agency Agreement (this “Agreement”) in connection with such issuance and sale. The Securities are more fully described in the Registration Statement, the Disclosure Package and the Prospectus (each as hereinafter defined).
